Education
About Us
Working with TipRanks
Follow Us
Addex Therapeutics (ADXN)
NASDAQ:ADXN
ADXN Stock Chart & Stats
$8.52
$0.23(2.80%)
At close: 4:00 PM EST
$8.52
$0.23(2.80%)
Day’s Range― - ―
52-Week Range$6.51 - $12.05
Previous CloseN/A
Volume26.36K
Average Volume (3M)45.37K
Market Cap
$8.96M
Enterprise Value$5.04M
Total Cash (Recent Filing)$2.30M
Total Debt (Recent Filing)$38.39K
Price to Earnings (P/E)0.8
Beta0.32
Next Earnings
Nov 10, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.02
Shares Outstanding1,536,287
10 Day Avg. Volume8,592
30 Day Avg. Volume45,366
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.54
Price to Sales (P/S)12.67
P/FCF Ratio-0.97
Enterprise Value/Market Cap0.56
Enterprise Value/Revenue30.96
Enterprise Value/Gross Profit751.26
Enterprise Value/Ebitda-1.04
Forecast
1Y Price Target
$8.50Price Target Upside-0.23% Downside
Rating ConsensusHold
Number of Analyst Covering0
Addex Therapeutics News
ADXN FAQ
What was Addex Therapeutics’s price range in the past 12 months?
Addex Therapeutics lowest stock price was $6.51 and its highest was $12.05 in the past 12 months.
What is Addex Therapeutics’s market cap?
Addex Therapeutics’s market cap is $8.96M.
When is Addex Therapeutics’s upcoming earnings report date?
Addex Therapeutics’s upcoming earnings report date is Nov 10, 2025 which is in 26 days.
How were Addex Therapeutics’s earnings last quarter?
Addex Therapeutics released its earnings results on Sep 30, 2025. The company reported -$3.016 earnings per share for the quarter, missing the consensus estimate of N/A by -$3.016.
Is Addex Therapeutics overvalued?
According to Wall Street analysts Addex Therapeutics’s price is currently Overvalued.
Does Addex Therapeutics pay dividends?
Addex Therapeutics does not currently pay dividends.
What is Addex Therapeutics’s EPS estimate?
Addex Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Addex Therapeutics have?
Addex Therapeutics has 1,536,287 shares outstanding.
What happened to Addex Therapeutics’s price movement after its last earnings report?
Addex Therapeutics reported an EPS of -$3.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.111%.
Which hedge fund is a major shareholder of Addex Therapeutics?
Among the largest hedge funds holding Addex Therapeutics’s share is New Leaf Venture Partners, L.L.C.. It holds Addex Therapeutics’s shares valued at 0.
Company Description
Addex Therapeutics
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
ADXN Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a balanced view with significant achievements in collaborative and strategic partnerships, financial stability, and progress in R&D. However, there were challenges related to decreased income, increased net loss from an associated venture, and limited cash for unpartnered programs.View all ADXN earnings summariesTechnical Analysis
Plus Therapeutics
―
Eterna Therapeutics
―
Minerva Neurosciences
―
GeoVax Labs
―
Moleculin Biotech
―
Ownership Overview
―
Insiders
―
Mutual Funds
0.07% Other Institutional Investors
99.93% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---